0001209191-23-009272.txt : 20230214 0001209191-23-009272.hdr.sgml : 20230214 20230214172544 ACCESSION NUMBER: 0001209191-23-009272 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Neil CENTRAL INDEX KEY: 0001742485 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 23631907 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-10 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 1 0 0 CEO and President Stock Option (Right to Buy) 11.41 2023-02-10 4 A 0 624652 0.00 A 2033-02-09 Common Stock 624652 624652 D Restricted Stock Units 2023-02-10 4 A 0 536704 0.00 A Common Stock 536704 536704 D The shares subject to this option vest and become exercisable in 48 equal monthly installments after February 10, 2023, such that all of the shares subject to the option shall be vested and exercisable on February 10, 2027, subject to the Reporting Person's continued service to the Issuer through each such date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date. /s/Brian C. Stephenson, Attorney-in-fact 2023-02-14